Healthy VolunteersPhase 2NCT02788227
Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine)
A Phase 2 study testing rVSV∆G-ZEBOV-GP Vaccine (V920) in people with Healthy Volunteers, run by National Institutes of Health Clinical Center (CC) at 3 sites in 2 countries.
Trial summary
Background: The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers
- What is being tested?
- rVSV∆G-ZEBOV-GP Vaccine (V920)
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 248 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 14 Oct 2016to 17 Jun 2025
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Any condition that would limit the ability of the participant to meet protocol requirements or would place the participant at unreasonable risk. Examples include:
- Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health, per the investigator. A clinically significant condition or process includes but is not limited to:
- A process that would adversely affect the systemic immune response
- A process that would require medication that might adversely affect the systemic immune response
- Any contraindication to repeated injections or blood draws
- A condition that requires active medical intervention or monitoring to avert grave danger to the participant's health or well-being during the study period
Show all 23Show fewer
- A condition or process for which signs or symptoms could be confused with reactions to vaccine
- Presence of any pre-existing illness or clinical history that, in the opinion of the investigator, would place the participant at an unreasonably increased risk through participation in this study. This includes but is not limited to:
- Active malignancy
- History of Guillain-Barre Syndrome
- History of neurological disorder that may increase risk (history of encephalitis, stroke, or seizure)
- Active autoimmune disorder requiring systemic immunosuppressive treatment
- Any concomitant medication for which reported side effects or adverse events, in the judgment of the investigator, may interfere with assessment of safety.
- Subjects who, in the judgment of the investigator, will be unlikely or unable to comply with the requirements of this protocol.
- Pregnant or breast feeding (must have negative serum or urine pregnancy test on the day of vaccination, prior to vaccination)
- Known allergy to the components of the rVSV∆G-ZEBOV-GP vaccine (V920) vaccine product (VSV, albumin, tris).
- History of severe local or systemic reactions to any vaccination.
- Received an investigational drug within 5 half-lives or 30 days, whichever is longer, prior to vaccination (Day 0)/booster (month 18).
- Received killed vaccines 14 days before, or intention to receive within 7 days following, vaccination (Day 0)/booster (month 18).
- Received live virus vaccines within 30 days before, or intention to receive live virus vaccines within 30 days following, vaccination (Day 0)/booster (month 18).
- Received immunoglobulins and/or any blood products within the 120 days preceding vaccination (Day 0)/booster (month 18).
- Received allergy treatment with antigen injections within 30 days before vaccination (Day 0)/booster (month 18).
- Clinical evidence (e.g. oral temp >38 degrees Celsius, systemic symptoms) of a systemic infection or other acute intercurrent illness at the proposed time of vaccination (Day 0)/booster (month 18).
Trial locations and contacts
3 sites in 2 countries.
3 sites in 2 countries
United States2 sites
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
The Hope Clinic of the Emory Vaccine Center, Emory University
Decatur, Georgia, 30030
Canada1 site
Health Canada, 539 John Buhler Research Center
Winnipeg, Manitoba, R3E 3P4
About this study
Official title: A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)
Background:
The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection. A vaccine to prevent infection either before or after exposure was approved in 2020 but the durability of the vaccine response is unknown. Researchers wish to study the potential to increase the antibody response to the licensed Ebola vaccine. An improved response before exposure to the virus potentially could increase the vaccine's effectiveness in preventing disease.
Read more
Objectives:
To see if the antibody response to the vaccine, rVSV∆G-ZEBOV-GP vaccine (V920), could potentially be improved by providing a booster injection several months after the primary immunization.
Eligibility:
Healthy adults at risk of exposure to the Ebola virus at work through lab or clinical contact.
Design:
- Participants will be screened with medical history, physical exam, and blood tests.
- Participants will get the study vaccine. It will be injected into their upper arm.
- Participants will be monitored closely for at least 30 minutes. They will get a diary card to record any symptoms they have from the vaccine for up to 14 days.
- Participants will have study visits at 1, 3, and 6 months after they get the vaccine, then every 6 months (that is, at months 12, 18, 19, 24, 30, and 36 of study) for a total of 36 months.
- Eighteen months after they join the study, participants will be randomly assigned to one of two groups. One group will get a second (or booster) dose of the vaccine. The other group will not get a second dose.
- This study lasts 36 months.
In December 2024, the study was approved to re-enroll up to 30 participants from the primary cohort to check longer-term immune response to the study vaccine beyond 36 months.
Read the detailed description
Between 1994 and the present, there have been multiple Ebola virus outbreaks affecting mostly central Africa. However, the 2014/2015 West African outbreak significantly exceeds all previous outbreaks in geographic range, number of individuals affected, and in disruption of typical activities of civil society.
This protocol is a multi-center study to evaluate the durability of the immune response following the open label administration of the rVSV∆G-ZEBOV-GP vaccine (V920) as pre-exposure prophylaxis for adults who have an occupational risk for potential exposure to Ebola virus. The vaccine uses a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola (rVSV∆G-ZEBOV-GP vaccine also known as V920).
All subjects will receive a single dose of rVSV∆G-ZEBOV-GP vaccine (V920) (>=7.2 x 10^7 pfu) on Day 0. We will collect adverse events after vaccination and at month 1 and month 19, serious adverse events (SAE) for the duration of the study, and assess the immune response at months 1, 3, 6, 12, 18, 19, 24, 30, and 36.
A single booster immunization with the same dose of study vaccine as the primary dose (>=7.2 x 10^7 pfu/mL) will be given to those randomized at month 18 to the booster arm of the trial. However, if at any time during the observation period antibody levels fall below a predefined seroprotective threshold (yet to be defined in parallel or newly planned studies), a booster will be offered to those who have not previously received a booster injection.
- Conditions
- Healthy Volunteers
- Being tested
- rVSV∆G-ZEBOV-GP Vaccine (V920)
- Keywords
- Ebola Vaccine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rVSV∆G-ZEBOV-GP Vaccine (V920)Biological
Primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1: Primary Immunization | Experimental | Adults deemed to be at current or future occupational risk (laboratory, clinical, or field) for exposure to Ebola virus received a single dose of rVSV∆G-ZEBOV-GP vaccine (V920) 1ml intramuscular injection in the deltoid muscle at the time of enrollment. Receives: Biological: rVSV∆G-ZEBOV-GP Vaccine (V920) |
| Arm 2a: Post Month 18: Boosted Group | Experimental | Participant were randomized at 18 months post primary immunization to receive a booster dose of rVSV∆G-ZEBOV-GP vaccine (V920) 1ml intramuscular injection in the deltoid muscle. Receives: Biological: rVSV∆G-ZEBOV-GP Vaccine (V920) |
| Arm 2b: Post Month 18: Non-boosted Group | No intervention | Participant were randomized at 18 months post primary immunization to not receive a booster dose of rVSV∆G-ZEBOV-GP vaccine (V920) vaccine. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Geometric Mean Antibody Titres
The geometric mean antibody titres (GMT) was measured by Filovirus Animal Nonclinical Group ELISA at month 36 months for the randomized study cohort.
Measured: Month 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2016 (estimated)
- Study start14 Oct 2016
- Primary completion17 Jun 2025
- Study completion17 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 248 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- Sponsor type
- US National Institutes of Health
- Collaborators
- Emory University, Health Canada
- Responsible party
- Sponsor
- Investigators
- Susan L Moir, Ph.D., Principal investigator, National Institute of Allergy and Infectious Diseases (NIAID)Nadine Rouphael, MD, MSc, Principal investigator, The Hope Clinic of the Emory Vaccine Center, Emory UniversityGuillaume Poliquin, MD, FRCPC, Principal investigator, Health Canada, 539 John Buhler Research Center, Winnipeg, Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02788227
- Sponsor's protocol ID
- 160053
- Other IDs
- 16-I-0053
- Status last verified
- 18 May 2026
- First submitted
- 28 May 2016
- Last updated
- 17 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Munoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutierrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVDeltaG-ZEBOV-GP Study Group. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.
PubMed 25830322Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaitre B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmuller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.
PubMed 25830326Davey RT Jr, Collins GL, Rouphael N, Poliquin G, McConnell R, Grubbs G, Moir SL, Langley JM, Teitelbaum M, Hewlett AL, McLellan SLF, Bhadelia N, Raabe VN, Mulligan MJ, Maljkovic Berry I, Dighero-Kemp B, Kurtz JR, Hensley LE, Dozier NCE, Marron LCB, DuChene A, Kuhn JH, Brown SK, Khurana S, Lane HC, Neaton JD. Safety and immunogenicity of a delayed booster dose of the rVSVDeltaG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial. Lancet Microbe. 2024 Nov;5(11):100923. doi: 10.1016/S2666-5247(24)00163-0. Epub 2024 Oct 4.
PubMed 39374605Raabe V, Lai L, Morales J, Xu Y, Rouphael N, Davey RT, Mulligan MJ. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVDeltaG-ZEBOV-GP). Vaccine. 2023 Feb 17;41(8):1513-1523. doi: 10.1016/j.vaccine.2023.01.059. Epub 2023 Jan 31.
PubMed 36725433
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)
- ClinicalTrials.gov ID
- NCT02788227
- Acronym / sponsor ID
- 160053
- Conditions
- Healthy Volunteers
- Keywords
- Ebola Vaccine
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 248 participants (actual)
- Lead sponsor
- National Institutes of Health Clinical Center (CC)US National Institutes of Health
- Collaborators
- Emory University, Health Canada
- Study start
- 14 Oct 2016 (actual)
- Primary completion
- 17 Jun 2025 (actual)
- Study completion
- 17 Jun 2025 (actual)
- First posted
- 2 Jun 2016 (estimated)
- Results
- Posted 17 Jun 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection. A vaccine to prevent infection either before or after exposure was approved in 2020 but the durability of the vaccine response is unknown. Researchers wish to study the potential to increase the antibody response to the licensed Ebola vaccine. An improved response before exposure to the virus potentially could increase the vaccine's effectiveness in preventing disease.
Objectives:
To see if the antibody response to the vaccine, rVSV∆G-ZEBOV-GP vaccine (V920), could potentially be improved by providing a booster injection several months after the primary immunization.
Eligibility:
Healthy adults at risk of exposure to the Ebola virus at work through lab or clinical contact.
Design:
- Participants will be screened with medical history, physical exam, and blood tests.
- Participants will get the study vaccine. It will be injected into their upper arm.
- Participants will be monitored closely for at least 30 minutes. They will get a diary card to record any symptoms they have from the vaccine for up to 14 days.
- Participants will have study visits at 1, 3, and 6 months after they get the vaccine, then every 6 months (that is, at months 12, 18, 19, 24, 30, and 36 of study) for a total of 36 months.
- Eighteen months after they join the study, participants will be randomly assigned to one of two groups. One group will get a second (or booster) dose of the vaccine. The other group will not get a second dose.
- This study lasts 36 months.
In December 2024, the study was approved to re-enroll up to 30 participants from the primary cohort to check longer-term immune response to the study vaccine beyond 36 months.
Detailed description
Between 1994 and the present, there have been multiple Ebola virus outbreaks affecting mostly central Africa. However, the 2014/2015 West African outbreak significantly exceeds all previous outbreaks in geographic range, number of individuals affected, and in disruption of typical activities of civil society.
This protocol is a multi-center study to evaluate the durability of the immune response following the open label administration of the rVSV∆G-ZEBOV-GP vaccine (V920) as pre-exposure prophylaxis for adults who have an occupational risk for potential exposure to Ebola virus. The vaccine uses a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola (rVSV∆G-ZEBOV-GP vaccine also known as V920).
All subjects will receive a single dose of rVSV∆G-ZEBOV-GP vaccine (V920) (>=7.2 x 10^7 pfu) on Day 0. We will collect adverse events after vaccination and at month 1 and month 19, serious adverse events (SAE) for the duration of the study, and assess the immune response at months 1, 3, 6, 12, 18, 19, 24, 30, and 36.
A single booster immunization with the same dose of study vaccine as the primary dose (>=7.2 x 10^7 pfu/mL) will be given to those randomized at month 18 to the booster arm of the trial. However, if at any time during the observation period antibody levels fall below a predefined seroprotective threshold (yet to be defined in parallel or newly planned studies), a booster will be offered to those who have not previously received a booster injection.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm 1: Primary Immunization | Experimental | Biological: rVSV∆G-ZEBOV-GP Vaccine (V920)Adults deemed to be at current or future occupational risk (laboratory, clinical, or field) for exposure to Ebola virus received a single dose of rVSV∆G-ZEBOV-GP vaccine (V920) 1ml intramuscular injection in the deltoid muscle at the time of enrollment. |
| Arm 2a: Post Month 18: Boosted Group | Experimental | Biological: rVSV∆G-ZEBOV-GP Vaccine (V920)Participant were randomized at 18 months post primary immunization to receive a booster dose of rVSV∆G-ZEBOV-GP vaccine (V920) 1ml intramuscular injection in the deltoid muscle. |
| Arm 2b: Post Month 18: Non-boosted Group | No intervention | –Participant were randomized at 18 months post primary immunization to not receive a booster dose of rVSV∆G-ZEBOV-GP vaccine (V920) vaccine. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (23 listed)
- Any condition that would limit the ability of the participant to meet protocol requirements or would place the participant at unreasonable risk. Examples include:
- Pregnant or breast feeding (must have negative serum or urine pregnancy test on the day of vaccination, prior to vaccination)
- Known allergy to the components of the rVSV∆G-ZEBOV-GP vaccine (V920) vaccine product (VSV, albumin, tris).
- History of severe local or systemic reactions to any vaccination.
- Received an investigational drug within 5 half-lives or 30 days, whichever is longer, prior to vaccination (Day 0)/booster (month 18).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rVSV∆G-ZEBOV-GP Vaccine (V920)Primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster. | Biological | Arm 1: Primary Immunization, Arm 2a: Post Month 18: Boosted Group |
Primary outcome
Geometric Mean Antibody Titres
Time frame: Month 36
The geometric mean antibody titres (GMT) was measured by Filovirus Animal Nonclinical Group ELISA at month 36 months for the randomized study cohort.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 25830322Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Munoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutierrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVDeltaG-ZEBOV-GP Study Group. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.
- Background: PubMed 25830326Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaitre B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmuller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.
- Results publication: PubMed 39374605Davey RT Jr, Collins GL, Rouphael N, Poliquin G, McConnell R, Grubbs G, Moir SL, Langley JM, Teitelbaum M, Hewlett AL, McLellan SLF, Bhadelia N, Raabe VN, Mulligan MJ, Maljkovic Berry I, Dighero-Kemp B, Kurtz JR, Hensley LE, Dozier NCE, Marron LCB, DuChene A, Kuhn JH, Brown SK, Khurana S, Lane HC, Neaton JD. Safety and immunogenicity of a delayed booster dose of the rVSVDeltaG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial. Lancet Microbe. 2024 Nov;5(11):100923. doi: 10.1016/S2666-5247(24)00163-0. Epub 2024 Oct 4.
- Derived from this study: PubMed 36725433Raabe V, Lai L, Morales J, Xu Y, Rouphael N, Davey RT, Mulligan MJ. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVDeltaG-ZEBOV-GP). Vaccine. 2023 Feb 17;41(8):1513-1523. doi: 10.1016/j.vaccine.2023.01.059. Epub 2023 Jan 31.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Healthy Volunteers
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Not yet recruitingObservational study
Screening Protocol
Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susan L Moir, Ph.D. principal investigator
National Institute of Allergy and Infectious Diseases (NIAID)
Nadine Rouphael, MD, MSc principal investigator
The Hope Clinic of the Emory Vaccine Center, Emory University
Guillaume Poliquin, MD, FRCPC principal investigator
Health Canada, 539 John Buhler Research Center, Winnipeg, Canada
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing rVSV∆G-ZEBOV-GP Vaccine (V920) in people with Healthy Volunteers, run by National Institutes of Health Clinical Center (CC) at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Geometric Mean Antibody Titres (time frame: Month 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02788227, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.